ARS Pharmaceuticals, Inc.
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
Allergic Reactions
Neffy
Adrenaline
PHASE4
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 600 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients with Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy |
Actual Study Start Date : | 2025-04-30 |
Estimated Primary Completion Date : | 2026-04 |
Estimated Study Completion Date : | 2026-06 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 4 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found